X4 Pharmaceuticals (XFOR) Other Operating Expenses (2017 - 2024)
X4 Pharmaceuticals (XFOR) posted Other Operating Expenses of $105.0 million for Q2 2024, up 20728.68% on a QoQ basis from -$509000.0 in Q4 2022.
X4 Pharmaceuticals (XFOR) Other Operating Expenses (2017 - 2024) Analysis & Trends
X4 Pharmaceuticals' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $105.0 million for Q2 2024.
- Quarterly Other Operating Expenses changed N/A year-over-year to $105.0 million in Q2 2024, while the trailing twelve-month figure through Mar 2025 was $105.0 million (changed N/A YoY) and the FY2024 annual result came in at $105.0 million, changed N/A from the prior year.
- Other Operating Expenses was $105.0 million for Q2 2024 at X4 Pharmaceuticals, up from -$509000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $105.0 million in Q2 2024 and bottomed at -$509000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn |
| 10 | X4 Pharmaceuticals | 166.21 Mn | -50.84 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 105.00 Mn |
| Dec 31, 2022 | -509,000.00 |
| Mar 31, 2022 | 509,000.00 |
| Dec 31, 2019 | 104,000.00 |
| Sep 30, 2019 | -4.00 Mn |
| Dec 31, 2017 | 13.89 Mn |